Return-to-activity rates cited in published case series range from 55–85%, depending on injury severity and pre-treatment duration of symptoms. Acute tears (≤3 months) tend to show better outcomes than chronic tendinopathy (>1 year). In the absence of blinded controls, distinguishing spontaneous healing from therapy-induced improvement remains difficult; many athletes also undergo structured physiotherapy concurrently.
The tendon-injury cell-therapy landscape encompasses 22 completed trials and 1 actively recruiting study. Most involve placental MSC injections or exosome preparations administered directly into the tendon lesion under ultrasound guidance. Trial cohorts typically include both acute partial tears and chronic degenerative tendinopathy. Imaging outcomes (ultrasound, MRI) in small studies show improved fibre continuity and reduced fluid signal in approximately 50–70% of treated tendons. Functional metrics (strength, pain reduction, return-to-activity) vary by trial; some report 60–80% of athletes returning to sport within 6–12 months, though untreated controls are rarely present for comparison.
Sunt un candidat? → · Tendon & Sports Injuries: full overview → · Cost Leziuni Tendinare și Răni Sportive → · Cost →
Revizuit medical de echipa editorială a StemCellAtlas cu Dr Tymur Lukyanenko (Orthopaedic Traumatologist · 20+ yrs clinical, 15+ yrs cell therapy) ale clinicii partenere Stem Plus (Sofia), în funcție de orientările ISSCR, FDA și EMA. Educational information, not medical advice; figures indicative.
Medicină regenerativă certificată GMP în inima UE — de la 3.000–8.000 €, o fracțiune din prețurile din SUA sau Germania. Protocoale personalizate pentru pacienți din peste 50 de țări.
Evaluare medicală gratuită